lncRNA AL133415.1在SH-SY5Y细胞中对波形蛋白基因表达调控的机制研究

doi:10.3969/j.issn.1003-9198.2026.02.005

Abstract

Abstract: Objective To investigate the effects of long non-coding RNA AL133415.1 (lncRNA AL133415.1) on cell viability, neuronal apoptosis and oxidative stress, and further explore its role in the molecular mechanism of Alzheimer’s disease (AD). Methods Amyloid β-protein (Aβ)_1-42-induced SH-SY5Y cells were selected to establish an AD cell model. The lncRNA AL133415.1 gene was regulated by plasmid transfection technology. Reverse transcription-polymerase chain reaction (RT-PCR) was used to detect the expression of lncRNA AL133415.1 and vimentin (VIM) gene in cells. Cell Counting Kit-8 (CCK-8) method was used to detect the proliferation rate of cells. Flow cytometry was used to detect cell apoptosis. DCFH-DA fluorescence assay was used to detect the levels of reactive oxygen species (ROS), superoxide dismutase (SOD), and malondialdehyde (MDA) in SH-SY5Y cells. Western Blot was used to detect the expression of VIM protein in the cells. Confocal laser scanning microscopy (CLSM) was used to detect the fluorescence intensity of VIM protein. Results The viability of SH-SY5Y cells was increased and their apoptosis rate was reduced in the lncRNA AL133415.1 inhibition group, while the viability of SH-SY5Y cells was significantly decreased and their apoptosis rate was increased in the lncRNA AL133415.1 overexpression group (all P<0.01). Down-regulation of lncRNA AL133415.1 expression could increase the intracellular SOD activity, while up-regulation would lead to a decrease in intracellular SOD activity; Down-regulation of lncRNA AL133415.1 expression could reduce the intracellular MDA and ROS activities, while up-regulation could increase the intracellular MDA and ROS activities (all P<0.05). Inhibition of lncRNA AL133415.1 expression could promote the expression of VIM gene, while overexpression would inhibit the expression of VIM gene (P<0.001). Conclusions Silencing of lncRNA AL133415.1 can promote the expression of VIM gene, while overexpression can inhibit the expression of VIM gene, which suggests that the expression of VIM gene can be indirectly regulated by regulating lncRNA AL133415.1, thereby reducing the incidence of AD.

Key words: Alzheimer’s disease, long non-coding RNA AL133415.1, vimentin, neuroinflammation

CLC Number:

R 749.16

CHENG Yi, ZOU Ting, LI Lihua, ZHANG Lei, ZHOU Xiaohui. Study on the mechanism of lncRNA AL133415.1 in regulating vimentin gene expression in SH-SY5Y cells[J]. Practical Geriatrics, 2026, 40(2): 126-131.

References

[1] 2023 Alzheimer’s disease facts and figures[J]. Alzheimers Dement, 2023, 19(4): 1598-1695.
[2] ANAND R, GILL K D, MAHDI A A. Therapeutics of Alzheimer’s disease: past, present and future[J]. Neuropharmacology, 2014, 76(Pt A): 27-50.
[3] JIA L, QUAN M, FU Y, et al. Dementia in China: epidemiology, clinical management, and research advances[J]. Lancet Neurol, 2020, 19(1): 81-92.
[4] 周晓辉, 洪玉, 马龙, 等. 新疆维吾尔自治区维汉两民族阿尔茨海默病和血管性痴呆的流行病学调查[J]. 中华神经科杂志, 2008, 41(12):797-801.
[5] TAN Z X, DONG F, WU L Y, et al. The beneficial role of exercise on treating Alzheimer’s disease by inhibiting β-amyloid peptide[J]. Mol Neurobiol, 2021, 58(11): 5890-5906.
[6] SCHELTENS P, DE STROOPER B, KIVIPELTO M, et al. Alzheimer’s disease[J]. Lancet, 2021, 397(10284): 1577-1590.
[7] WANG L K, CHEN X F, HE D D, et al. Dissection of functional lncRNAs in Alzheimer’s disease by construction and analysis of lncRNA-mRNA networks based on competitive endogenous RNAs[J]. Biochem Biophys Res Commun, 2017, 485(3): 569-576.
[8] LUO O J, LEI W, ZHU G, et al. Multidimensional single-cell analysis of human peripheral blood reveals characteristic features of the immune system landscape in aging and frailty[J]. Nat Aging, 2022, 2(4): 348-364.
[9] CRIST A M, HINKLE K M, WANG X, et al. Transcriptomic analysis to identify genes associated with selective hippocampal vulnerability in Alzheimer’s disease[J]. Nat Commun, 2021, 12(1): 2311.
[10] LIU N X, LI Q H. LncRNA BC200 regulates neuron apoptosis and neuroinflammation via PI3K/AKT pathway in Alzheimer’s disease[J]. J Biol Regul Homeost Agents, 2020, 34(6): 2255-2261.
[11] CAO Q, GUO Z, YAN Y, et al. Exosomal long noncoding RNAs in aging and age-related diseases[J]. IUBMB Life, 2019, 71(12): 1846-1856.
[12] CHENG Y, ZHOU X, ZOU T, et al. Plasma long non-coding RNAs ASMTL-AS1, AP001363.1, AC005730.3 and AL133415.1 as a potential biomarker for Alzheimer’s disease[J]. Neurol Res, 2023, 45(9): 804-817.
[13] DANIELSSON F, PETERSON M K, CALDEIRA ARAÚJO H, et al. Vimentin diversity in health and disease[J]. Cells, 2018, 7(10): 147.
[14] SATELLI A, LI S. Vimentin in cancer and its potential as a molecular target for cancer therapy[J]. Cell Mol Life Sci, 2011, 68(18): 3033-3046.
[15] TANAKA H, GOTO H, INOKO A, et al. Cytokinetic failure-induced tetraploidy develops into aneuploidy, triggering skin aging in phosphovimentin-deficient mice[J]. J Biol Chem, 2015, 290(21): 12984-12998.
[16] LEVIN E C, ACHARYA N K, SEDEYN J C, et al. Neuronal expression of vimentin in the Alzheimer’s disease brain may be part of a generalized dendritic damage-response mechanism[J]. Brain Res, 2009, 1298: 194-207.
[17] COURBOULIN A, RANCHOUX B, COHEN-KAMINSKY S, et al. microRNA networks in pulmonary arterial hypertension: share mechanisms with cancer?[J]. Curr Opin Oncol, 2016, 28(1): 72-82.
[18] ZHU H, CAO Y, SU W, et al. Enterovirus A71 VP1 variation A289T decreases the central nervous system infectivity via attenuation of interactions between VP1 and vimentin in vitro and in vivo[J]. Viruses, 2019, 11(5): 467.
[19] 刘震,朱海宏. LncRNA在部分肿瘤中的差异表达及与mRNA结合作用关系的研究现状[J]. 临床医学进展, 2023, 13(10): 16826-16832.
[20] ZHANG F, CAI Y, DIAO B, et al. Long non-coding RNA NLIPMT as a tumor suppressor and inhibitor of cell proliferation and metastasis in papillary thyroid carcinoma[J]. Cancer Manag Res, 2020, 12: 10311-10319.
[21] YANG Y, CHEN Q, PIAO H Y, et al. HNRNPAB-regulated lncRNA-ELF209 inhibits the malignancy of hepatocellular carcinoma[J]. Int J Cancer, 2020, 146(1): 169-180.
[22] WANG X, ZHANG M, LIU H. LncRNA17A regulates autophagy and apoptosis of SH-SY5Y cell line as an in vitro model for Alzheimer’s disease[J]. Biosci Biotechnol Biochem, 2019, 83(4): 609-621.

Study on the mechanism of lncRNA AL133415.1 in regulating vimentin gene expression in SH-SY5Y cells

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Recommended 10

[1]	SUN Yang, GUO Ying. Research progress on drug targets for Alzheimer’s disease-related cognitive impairment [J]. Practical Geriatrics, 2026, 40(2): 116-120.
[2]	LUO Jing, ZHANG Yufeng, GAO Xiaolong, GU Guojun. Application of amide proton transfer magnetic resonance imaging in early diagnosis of Alzheimer’s disease [J]. Practical Geriatrics, 2026, 40(2): 164-168.
[3]	YANG Xin, SHI Shengliang. Research progress on the pathways of enhancing and restoring lysosomal function in Alzheimer’s disease [J]. Practical Geriatrics, 2026, 40(2): 180-184.
[4]	WANG Miaohui, FAN Xuhang, CHEN Siyao, YANG Xiaojuan. Research progress on the correlation between Alzheimer’s disease and osteoporosis [J]. Practical Geriatrics, 2025, 39(9): 937-941.
[5]	YANG Huijuan, LIU Shunying, SU Jing, ZENG Liting. Advances in the application of artificial intelligence in the full-course management of Alzheimer’s disease [J]. Practical Geriatrics, 2025, 39(8): 768-772.
[6]	ZHONG Yi, FENG Yue, ZHANG Xinlong, DING Rui, SI Yanna. Research progress in single-cell RNA sequencing for Alzheimer’s disease [J]. Practical Geriatrics, 2025, 39(8): 857-861.
[7]	GU Xingyue, GAO Wei, LU Xiang. Advances in the study of enzymatic protein glycosylation in Alzheimer’s disease [J]. Practical Geriatrics, 2025, 39(6): 631-635.
[8]	WANG Yun, FU Liping. Significance of retinal structural and functional changes in the diagnosis of Alzheimer’s disease in high-altitude regions [J]. Practical Geriatrics, 2025, 39(5): 461-465.
[9]	WANG Yan, XU Jie, GU Xiaoping. Research advances on association between fatty acid metabolism and Alzheimer’s disease [J]. Practical Geriatrics, 2025, 39(4): 415-419.
[10]	LIN Xiaoqi, ZHAO Xinjing, WU Yashuang, ZHAO Wei, CHEN Chen, GAO Tianyu, ZHOU Guoyu. Advances of the mechanisms of gender differences in Alzheimer’s disease [J]. Practical Geriatrics, 2025, 39(4): 420-425.
[11]	CHEN Pengyao, ZHAO Ziwei, ZHAN Xianghong, LIU Yong. Role of insulin resistance in different brain regions in Alzheimer’s disease [J]. Practical Geriatrics, 2025, 39(11): 1163-1168.
[12]	YUAN Lili, ZOU Qiangwei. Advances in multi-omics research on Alzheimer’s disease [J]. Practical Geriatrics, 2025, 39(10): 1003-1008.
[13]	LI Qingyang, WANG Chanjuan, WANG Zheng. Study on the correlation of cognitive function with swallowing function and nutritional status in the elderly patients with Alzheimer’s disease [J]. Practical Geriatrics, 2024, 38(6): 577-581.
[14]	LIU Tian, YANG Rongli, HAN Huiping. Value of serum levels of Aβ1-42 and Bcl-2 in predicting the pathogenesis of Alzheimer’s disease in elderly patients with cognitive impairment [J]. Practical Geriatrics, 2024, 38(6): 582-586.
[15]	WANG Bingsheng, CAO Shihua, CHENG Lingling, SHI Aili, SHI Yankai, YAO Jiani, LOU Xiajing, QI Wenhao, DONG Chaoqun, ZHU Xiaohong, WANG Bing, HE Danni, CHEN Yanfei. A nomogram prediction model for risk of Alzheimer’s disease among the elderly [J]. Practical Geriatrics, 2024, 38(12): 1246-1249.